| Intrinsic subtype switching and acquired ERBB2/HER2 amplifications and mutations in breast cancer brain metastases N Priedigkeit, RJ Hartmaier, Y Chen, D Vareslija, A Basudan, RJ Watters, ... JAMA oncology 3 (5), 666-671, 2017 | 174 | 2017 |
| Comprehensive evaluation of fusion transcript detection algorithms and a meta-caller to combine top performing methods in paired-end RNA-seq data S Liu, WH Tsai, Y Ding, R Chen, Z Fang, Z Huo, SH Kim, T Ma, TY Chang, ... Nucleic acids research 44 (5), e47-e47, 2016 | 166 | 2016 |
| Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer RJ Hartmaier, SE Trabucco, N Priedigkeit, JH Chung, CA Parachoniak, ... Annals of oncology 29 (4), 872-880, 2018 | 115 | 2018 |
| Exome-capture RNA sequencing of decade-old breast cancers and matched decalcified bone metastases N Priedigkeit, RJ Watters, PC Lucas, A Basudan, R Bhargava, W Horne, ... JCI Insight 2 (17), https://insight.jci.org/articles/view/95, 2017 | 115 | 2017 |
| Transcriptome characterization of matched primary breast and brain metastatic tumors to detect novel actionable targets D Varešlija, N Priedigkeit, A Fagan, S Purcell, N Cosgrove, PJ O’Halloran, ... JNCI: Journal of the National Cancer Institute 111 (4), 388-398, 2019 | 102 | 2019 |
| Inhibition of the nuclear export receptor XPO1 as a therapeutic target for platinum-resistant ovarian cancer Y Chen, SC Camacho, TR Silvers, ARA Razak, NY Gabrail, JF Gerecitano, ... Clinical Cancer Research 23 (6), 1552-1563, 2017 | 85 | 2017 |
| The CARMA3–Bcl10–MALT1 Signalosome drives NFκB activation and promotes aggressiveness in angiotensin II receptor–positive breast cancer P Ekambaram, JY Lee, NE Hubel, D Hu, S Yerneni, PG Campbell, ... Cancer research 78 (5), 1225-1240, 2018 | 80 | 2018 |
| Personalized ovarian cancer disease surveillance and detection of candidate therapeutic drug target in circulating tumor DNA JA Martignetti, O Camacho-Vanegas, N Priedigkeit, C Camacho, ... Neoplasia 16 (1), 97-W29, 2014 | 78 | 2014 |
| Morbid obesity resulting from inactivation of the ciliary protein CEP19 in humans and mice A Shalata, MC Ramirez, RJ Desnick, N Priedigkeit, C Buettner, C Lindtner, ... The American Journal of Human Genetics 93 (6), 1061-1071, 2013 | 78 | 2013 |
| Forkhead box Q1 is a novel target of breast cancer stem cell inhibition by diallyl trisulfide SH Kim, CH Kaschula, N Priedigkeit, AV Lee, SV Singh Journal of Biological Chemistry 291 (26), 13495-13508, 2016 | 72 | 2016 |
| FGFR4 overexpression and hotspot mutations in metastatic ER+ breast cancer are enriched in the lobular subtype KM Levine, N Priedigkeit, A Basudan, N Tasdemir, MJ Sikora, ES Sokol, ... NPJ breast cancer 5 (1), 19, 2019 | 60 | 2019 |
| ESR1 mutant breast cancers show elevated basal cytokeratins and immune activation Z Li, O McGinn, Y Wu, A Bahreini, NM Priedigkeit, K Ding, S Onkar, ... Nature Communications 13 (1), 2011, 2022 | 47 | 2022 |
| Hotspot ESR1 Mutations Are Multimodal and Contextual Modulators of Breast Cancer Metastasis Z Li, Y Wu, ME Yates, N Tasdemir, A Bahreini, J Chen, KM Levine, ... Cancer research 82 (7), 1321-1339, 2022 | 46 | 2022 |
| Nucleo-cytoplasmic localization domains regulate Krüppel-like factor 6 (KLF6) protein stability and tumor suppressor function E Rodríguez, N Aburjania, NM Priedigkeit, A DiFeo, JA Martignetti PLoS One 5 (9), e12639, 2010 | 43 | 2010 |
| Frequent ESR1 and CDK pathway copy-number alterations in metastatic breast cancer A Basudan, N Priedigkeit, RJ Hartmaier, ES Sokol, A Bahreini, RJ Watters, ... Molecular Cancer Research 17 (2), 457-468, 2019 | 41 | 2019 |
| Single-cell transcriptomic heterogeneity in invasive ductal and lobular breast cancer cells F Chen, K Ding, N Priedigkeit, A Elangovan, KM Levine, N Carleton, ... Cancer research 81 (2), 268-281, 2021 | 40 | 2021 |
| Evolutionary signatures amongst disease genes permit novel methods for gene prioritization and construction of informative gene-based networks N Priedigkeit, N Wolfe, NL Clark PLoS genetics 11 (2), e1004967, 2015 | 27 | 2015 |
| Acquired mutations and transcriptional remodeling in long-term estrogen-deprived locoregional breast cancer recurrences N Priedigkeit, K Ding, W Horne, JK Kolls, T Du, PC Lucas, JU Blohmer, ... Breast Cancer Research 23, 1-14, 2021 | 23 | 2021 |
| HER2-low inflammatory breast cancer: Clinicopathologic features and prognostic implications P Tarantino, SM Niman, TK Erick, N Priedigkeit, BT Harrison, A Giordano, ... European Journal of Cancer 174, 277-286, 2022 | 20 | 2022 |
| Single cell heterogeneity and evolution of breast cancer bone metastasis and organoids reveals therapeutic targets for precision medicine K Ding, F Chen, N Priedigkeit, DD Brown, K Weiss, R Watters, KM Levine, ... Annals of Oncology 33 (10), 1085-1088, 2022 | 16 | 2022 |
Adam BrufskyProfessor of Medicine, University of PittsburghBestätigte E-Mail-Adresse bei upmc.edu
